Revenio Group Corporation: Revenio Group Corporation’s shareholders will be able to watch the Annual General Meeting on March 19, 2020 by video link

Revenio Group Corporation, Stock Exchange Release, March 13, 2020 at 14:00

Revenio Group Corporation’s shareholders will be able to watch the Annual General Meeting on March 19, 2020 by video link


Revenio Group Corporation's Annual General Meeting will be held on Thursday, March 19, 2020, at 4:00 pm at the Finlandia Hall, Veranda 2 Hall, Mannerheimintie 13e, 00100 Helsinki (entrance M4 / K4). Reception of the participants of the meeting and distribution of the voting tickets will begin at 3 pm.


Due to the situation caused by the coronavirus and in support of the recommendations made by the authorities, Revenio offers its shareholders the opportunity to follow the Annual General Meeting by video link.


Revenio shareholders have the opportunity to watch the Annual General Meeting by video. It is important to note that following a meeting via video link, a shareholder will not attend the meeting and will not be able to exercise his / her right to question under the Companies Act, even if he / she has registered for the Annual General Meeting. This is not a case of remote participation under the Companies Act, but the opportunity provided by Revenio to watch the general meeting by video link. Watching the meeting via video requires the shareholder to identify with a Finnish bank code or mobile certificate when signing up.


Link to the Annual General Meeting video link:


Unlike the notice to the Annual General Meeting, Revenio will not hold a coffee meeting after the meeting for the above reason. The company will follow the government guidelines on the development of the coronavirus situation and take further action if necessary.


Revenio Group Corporation

Board of Directors


Further information:

CEO and President Timo Hildén

tel. +358 40 580 4774



Nasdaq Helsinki Ltd

Financial Supervisory Authority

Main media


Revenio Group in brief


Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.


The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.


The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.


In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.